公开(公告)号：WO2019156616A1

公开(公告)日：2019-08-15

申请号：PCT/SE2019/050098

申请日：2019-02-06

Applicant: MAQUET CRITICAL CARE AB

Inventor： HALLBÄCK, Magnus

IPC: A61M16/00 ,  A61M16/12

CPC classification number: A61M16/024 ,  A61M16/12 ,  A61M16/204 ,  A61M16/205 ,  A61M2016/0027 ,  A61M2016/0039 ,  A61M2016/0042 ,  A61M2205/50 ,  A61M2205/502 ,  A61M2205/505 ,  A61M2205/52

Abstract: The present disclosure relates to a method for controlling a ventilator arrangement. The method might be suitable for maintaining or achieving a desired end expiratory lung volume, EELV, of a subject when an external manoeuvre is performed on the subject ventilated by the ventilator arrangement. The ventilator arrangement applies a set positive end-expiratory pressure, PEEP, level for performing the ventilation.

公开(公告)号：WO2019126721A1

公开(公告)日：2019-06-27

申请号：PCT/US2018/067240

申请日：2018-12-21

Applicant: ABIOMED, INC.

Inventor： LIU, Chen ,  KATERJI, Admad El ,  CORBETT, Scott

IPC: G16H20/40 ,  A61M5/14 ,  G16H20/17 ,  G16H50/00 ,  A61M1/10

CPC classification number: A61M1/1086 ,  A61B5/00 ,  A61M1/101 ,  A61M1/1031 ,  A61M1/122 ,  A61M1/125 ,  A61M2205/04 ,  A61M2205/18 ,  A61M2205/3303 ,  A61M2205/3365 ,  A61M2205/50 ,  A61M2205/502 ,  A61M2205/52 ,  A61M2205/584 ,  A61M2230/06 ,  A61M2230/20 ,  A61M2230/208 ,  A61M2230/30 ,  A61M2230/43 ,  G06N5/045 ,  G06N20/00 ,  G16H20/17 ,  G16H20/40 ,  G16H50/00 ,  G16H50/20

Abstract: Systems and methods are provided herein for treating a patient in cardiogenic shock. An intravascular heart pump system is inserted into vasculature of the patient. The heart pump system has a cannula, pump outlet, pump inlet, and rotor. The heart pump system is positioned within the patient such that the cannula extends across the patient's aortic valve, the pump inlet is located within the patient's left ventricle, and the pump outlet is located within the patient's aorta. Data related to time-varying parameters of the heart pump system is acquired from the heart pump system. A plurality of features are extracted from the data. A probability of survival of the patient is determined based on the plurality of features and using a prediction model. The heart pump system is operated to treat the patient.

公开(公告)号：WO2019115570A1

公开(公告)日：2019-06-20

申请号：PCT/EP2018/084439

申请日：2018-12-12

Applicant: KONINKLIJKE PHILIPS N.V.

Inventor： ROMANO, Robert

IPC: A61M16/10 ,  A61B5/083 ,  A61M16/00 ,  A61B5/024 ,  A61M16/20

CPC classification number: A61M16/101 ,  A61B5/02416 ,  A61B5/0833 ,  A61B5/1102 ,  A61B5/4836 ,  A61B5/681 ,  A61M16/024 ,  A61M16/0666 ,  A61M16/1005 ,  A61M16/202 ,  A61M2016/0027 ,  A61M2016/1025 ,  A61M2202/0208 ,  A61M2205/3306 ,  A61M2205/3331 ,  A61M2205/3584 ,  A61M2205/3592 ,  A61M2205/52 ,  A61M2230/04 ,  A61M2230/06 ,  A61M2230/205 ,  A61M2230/42 ,  A61M2230/63 ,  A61M2230/005 ,  A61M2202/0007

Abstract: An oxygen delivery system (100) provides controlled flow of oxygen- enriched gas to a patient (P). The system comprises one or more sensors (106a, 106n) configured to measure respiration rate information and heart rate information of the patient. A computer system (102) comprising one or more physical processors is operatively connected with the sensors. The physical processors are programmed with computer program instructions which, when executed cause the computer system to determine (304) a metabolic oxygen consumption information of the patient from the respiration rate information and the heart rate information from the one or more sensors, and continuously adjust (306) flow, volume and/or pressure of the oxygen-enriched gas delivered from an oxygen source (176) of the oxygen delivery system to the patient based on the determined metabolic oxygen consumption information of the patient.

公开(公告)号：WO2019082083A2

公开(公告)日：2019-05-02

申请号：PCT/IB2018/058263

申请日：2018-10-23

Applicant: ONEFUSION AG

Inventor： LÄNGLE, Daniel ,  GARTMANN, Jonas

IPC: A61M5/142 ,  A61M5/14 ,  A61M5/168

CPC classification number: A61M5/14228 ,  A61M5/1411 ,  A61M5/1415 ,  A61M5/16881 ,  A61M5/1689 ,  A61M39/281 ,  A61M2205/128 ,  A61M2205/3334 ,  A61M2205/3553 ,  A61M2205/502 ,  A61M2205/52 ,  A61M2205/6009 ,  A61M2205/6072 ,  A61M2205/8206 ,  A61M2209/082

Abstract: In some implementations, an infusion device includes a housing, a tube engagement assembly defining a channel to receive an infusion tube, a valve member movably coupled to the tube engagement assembly and positioned to press on an outside of the infusion tube while the infusion tube is engaged in the channel, and a valve actuator motor fixedly coupled with the housing. The tube engagement assembly can be movably coupled with the housing between: (i) an open configuration and (ii) a closed configuration. The valve actuator motor can be positioned to: (i) be operably engaged with the valve member while the tube engagement assembly is in the closed configuration and (ii) be inoperably unengaged from the valve member while the tube engagement assembly is in the open configuration.

公开(公告)号：WO2019068780A2

公开(公告)日：2019-04-11

申请号：PCT/EP2018/076935

申请日：2018-10-03

Applicant: PROJECT PARADISE LIMITED

Inventor： LAWSON, David ,  DIGNUM, Mark

IPC: A24F47/00 ,  A61M11/04 ,  A61M15/00 ,  A61M15/06 ,  B05B17/06

CPC classification number: A61M11/042 ,  A24F47/002 ,  A24F47/008 ,  A61M11/005 ,  A61M15/0065 ,  A61M15/0085 ,  A61M15/06 ,  A61M2205/3317 ,  A61M2205/3331 ,  A61M2205/3368 ,  A61M2205/50 ,  A61M2205/52 ,  A61M2205/581 ,  A61M2205/583 ,  A61M2205/702 ,  B05B17/0607

Abstract: An excitation device for an electronic inhaler is disclosed. The excitation device is designed to be disposable and is pre-dosed with an amount of a formulation including nicotine which is to be at least partially aerosolised by an excitation device when supplied with an excitation energy. The excitation device consists of a substrate material to one side of which is fixedly applied an excitation means comprising one or more contact portions by means of which an appropriate energy source can be connected and at least one excitation element over which the said amount of formulation is applied, said one or more contact portions being connected or otherwise in communication with said at least one excitation element such that energy received through the one or more contact portions is communicated to the at least one excitation element causing sufficient excitement to cause at least partially aerosolisation of any formulation extant thereon. In accordance with the invention, the formulation is disposed and applied over only the excitation element, as opposed to the contact portions, so as to be in direct physical contact therewith such that at least one measurable physical property of the excitation element, usually an electrical property such as resistance when the excitation element is electrically powered, is modulated to at least some degree by virtue of said direct physical contact so that measuring the physical characteristic provides an indication of the remaining volume of formulation extant on the excitation element. Both the substrate and the at least one excitation element are substantially chemically inert as regards the formulation so that the chemistry of the formulation is not changed between successive excitations. A method of electronically controlling such excitation device of an electronic inhaler, and an electronic control circuit therefor, are also disclosed.

公开(公告)号：WO2019023549A1

公开(公告)日：2019-01-31

申请号：PCT/US2018/044043

申请日：2018-07-27

Applicant: L'OREAL ,  GEORGE, Kelly

Inventor： GEORGE, Kelly ,  MILLER, Zane ,  WANGARI-TALBOT, Janet ,  GREEN, Destenee

IPC: A61M1/00 ,  A61H23/00 ,  A61N1/18 ,  A61B5/053 ,  A61H7/00 ,  A61H9/00

CPC classification number: A61H9/0057 ,  A45D44/22 ,  A61B5/0537 ,  A61B5/682 ,  A61H7/008 ,  A61H9/0007 ,  A61H23/00 ,  A61H2201/165 ,  A61H2205/022 ,  A61M1/0025 ,  A61M1/0031 ,  A61M1/0037 ,  A61M1/0068 ,  A61M1/0072 ,  A61M1/0088 ,  A61M1/08 ,  A61M2205/05 ,  A61M2205/054 ,  A61M2205/3553 ,  A61M2205/364 ,  A61M2205/52 ,  A61M2210/0625 ,  A61M2230/005 ,  A61M2230/63 ,  A61M2230/65 ,  A61N1/0452 ,  A61N1/18 ,  A61N1/328

Abstract: A lip conditioning device for providing enhanced tissue therapy to lip tissue of a user, the device including a mouthpiece having a chamber with a distal end configured to create a seal with a portion of lip tissue of a user; a base portion, connected to the mouthpiece, including a controller in communication with a power source, and a suction device configured to remove air within the chamber; and a set of controls, in communication with the controller, configured to control a mode of operation of the tissue therapy.

公开(公告)号：WO2019010350A1

公开(公告)日：2019-01-10

申请号：PCT/US2018/040985

申请日：2018-07-06

Applicant: THE JOHNS HOPKINS UNIVERSITY

Inventor： MARASCALCHI, Bryan J.

IPC: A61M16/00 ,  A61B5/08

CPC classification number: A61M16/0075 ,  A61B5/085 ,  A61B5/091 ,  A61B5/4836 ,  A61B5/743 ,  A61B2505/01 ,  A61M16/00 ,  A61M16/0084 ,  A61M16/024 ,  A61M16/208 ,  A61M2016/0027 ,  A61M2016/0036 ,  A61M2205/3375 ,  A61M2205/3569 ,  A61M2205/3592 ,  A61M2205/502 ,  A61M2205/505 ,  A61M2205/52 ,  A61M2205/8206

Abstract: An embodiment in accordance with the present invention provides a monitor for use with a bag valve mask (BVM). In some embodiments, the monitor can take the form of an inline electronic spirometer using a bi-directional digital turbine for the BVM with volume, pressure, and respiratory rate alarms and active real time monitoring in order to prevent volutrauma/barotrauma and hypoxia. Alternatively, an out of line electronic spirometer using a variable orifice or fixed orifice flowmeter (pitot tube) and two tubes connected to a portable device can be used. The monitor can come with a BVM or can be a separate device configured for coupling to an existing BVM.

公开(公告)号：WO2018228932A1

公开(公告)日：2018-12-20

申请号：PCT/EP2018/065126

申请日：2018-06-08

Applicant: NOVO NORDISK A/S

Inventor： BJÖRK, ARADÓTTIR, Tinna ,  BENGTSSON, Henrik ,  LIND, JENSEN, Morten ,  BROCKMEIER, Pete

IPC: G16H20/17 ,  A61B5/145 ,  G16H50/20

CPC classification number: G16H20/17 ,  A61B5/0004 ,  A61B5/14532 ,  A61B5/4839 ,  A61M5/1723 ,  A61M2005/1726 ,  A61M2205/3306 ,  A61M2205/3507 ,  A61M2205/3561 ,  A61M2205/3569 ,  A61M2205/3584 ,  A61M2205/50 ,  A61M2205/52 ,  A61M2205/8206 ,  G16H50/20

Abstract: Systems and methods are provided for adjusting long acting insulin medicament dosages for a subject. A plurality of timestamped glucose measurements of the subject is obtained. A titration glucose level (246) is computed as a measure of central tendency (244, 268, 274) of a titration subset of small glucose measurements (240, 269, 273) identified within the timestamped glucose measurements, wherein the measure of central tendency represents a measure of small glucose measurements for the primary time window. A long acting insulin medicament dosage (216) is adjusted or maintained based upon the obtained titration glucose level (246).

公开(公告)号：WO2018222589A1

公开(公告)日：2018-12-06

申请号：PCT/US2018/034880

申请日：2018-05-29

Applicant: A.Y.Y.T. - TECHNOLOGICAL APPLICATIONS AND DATA UPDATE, LTD. ,  M&B IP ANALYSTS, LLC

Inventor： KOHEN-VACS, Dan, R. ,  BEN-AHARON, Oren ,  BARTOV, Amit

IPC: A61B5/00 ,  A61M21/00 ,  G16H20/00

CPC classification number: A61B5/02055 ,  A61B5/4836 ,  A61B5/7267 ,  A61M21/00 ,  A61M2021/0027 ,  A61M2021/005 ,  A61M2205/3553 ,  A61M2205/3561 ,  A61M2205/507 ,  A61M2205/52 ,  A61M2230/04 ,  A61M2230/18 ,  A61M2230/30 ,  A61M2230/42 ,  A61M2230/50 ,  G16H20/00 ,  G16H20/70 ,  G16H40/63 ,  G16H40/67 ,  G16H50/70

Abstract: A system and method for treating disorders. The system includes a head mounted device (HMD) configured to be worn on the head of a user, the HMD including an internal display for displaying scenes; at least one biofeedback sensor, wherein the at least one biofeedback sensor is configured to monitor physiological responses of the user; a server connected to the HMD and the at least one biofeedback sensor, the server further including; a processing circuitry; and a memory, the memory containing instructions that, when executed by the processing circuitry, configure the system to: determine stimuli based on a current treatment session goal; send the stimuli to the HMD; receive input data from the at least one biofeedback sensor; update the current session goal based on the received input data; and send updated stimuli to the HMD based on the updated current treatment session goal.

公开(公告)号：WO2018166712A1

公开(公告)日：2018-09-20

申请号：PCT/EP2018/052802

申请日：2018-02-05

Applicant: NOVARTIS AG

Inventor： SCHMIDLIN, Alain ,  IOBBI, Mario ,  STUDER, Erich ,  BRYANT, Andrew ,  DEODHAR, Chinmay ,  PATEL, Rajan ,  COENDET, Samuel ,  GAJERA, Vivek ,  PARMAR, Prakash

IPC: G06F19/00 ,  G16H40/63 ,  G16H40/67 ,  G16H40/40 ,  G16H20/13 ,  A61J1/00 ,  A61M5/14 ,  G06K19/077

CPC classification number: G16H20/13 ,  A61M5/14 ,  A61M5/172 ,  A61M5/20 ,  A61M5/31566 ,  A61M5/31571 ,  A61M2205/3576 ,  A61M2205/3584 ,  A61M2205/3592 ,  A61M2205/50 ,  A61M2205/502 ,  A61M2205/52 ,  A61M2205/60 ,  A61M2205/6063 ,  A61M2205/6072 ,  G06K7/10356 ,  G06K19/07773 ,  G16H40/40 ,  G16H40/63 ,  G16H40/67

Abstract: A medical device (100) comprises a container receiver unit (110) configured to receive and hold a container (120), wherein the container (120) accommodates a pharmaceutical product (125) and comprises a first communication tag (130) configured to store information regarding the pharmaceutical product (125), a reader unit (140) configured to wirelessly read the information from the first communication tag (130), and a control unit (150) configured to control the medical device (100) based on the information read from the first communication tag (130). The medical device (100) further comprises an opening or a transparent window (165) allowing to at least partially see from the outside the container (120) inserted into the container receiver unit (110), wherein the reader unit (140) comprises a first antenna unit (142, 144), and the container (120) inserted into the container receiver unit (110) is located between (i) the opening or the transparent window (165) and (ii) the first antenna unit (142, 144).